MissionIRNewsBreaks – SRAX Inc. (NASDAQ: SRAX) Ahead of Curve in New California Compliancy Law

Digital marketing and consumer-data-management technology company SRAX (NASDAQ: SRAX) is staying a step ahead of the competition as new privacy laws come into play in California. An article discussing the company reads, “While other companies are adjusting budgets to cover the cost of compliancy to a new California law by January 1, 2020, BIGtoken has already sidestepped the legal data issue because it requests users’ permission for data sharing when those users initially sign up for the platform. BIGtoken puts control in the hands of the consumer by providing the right to privacy, awareness and choice from the get-go (http://ibn.fm/KG5zt). Once users sign up, they are able to determine and make decisions on how much of their information is shared and to whom. For SRAX, privacy has always been a right. . . . Doing the right thing from day one has placed SRAX a step ahead in the industry. Competitors in digital marketing and consumer data management will be spending up to $55 billion to comply with the California Consumer Privacy Act (CCPA) (http://ibn.fm/LtGNZ). The bill gives California residents the right to be informed about how companies gather and use their data, an ideal that is an integral component of BIGtoken’s core mission. BIGtoken has been building consumers’ trust, resulting in an increase of consumer opted-in data made available to brands, making that data far more valuable than information collected through data mining.”

To view the full article, visit http://ibn.fm/hV8OZ

About SRAX Inc.

SRAX (NASDAQ: SRAX) is a digital marketing and consumer-data-management technology company. SRAX’s technology unlocks data to reveal brands’ core consumers and the characteristics of those consumers across marketing channels. Monetizing its data sets, SRAX is growing multiple recurring revenue streams through its various platforms. Through its BIGtoken platform, SRAX has developed a consumer-managed data marketplace where people can own and earn from their data, thereby offering everyone in the internet ecosystem choice, transparency and compensation. SRAX’s tools deliver a digital competitive advantage for brands in the CPG, automotive, investor relations, luxury and lifestyle verticals by integrating all aspects of the advertising experience, including verified consumer participation, into one platform. For more information, visit the company’s website at www.SRAX.com.

NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://ibn.fm/SRAX

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

The Green Organic Dutchman Holdings Ltd. (TSX: TGOD) (OTCQX: TGODF) Adjusts Construction Roadmap for Agile Capacity Management

• The company has unveiled a new strategic plan to reduce its financing requirements while continuing on the path to profitability
• TGOD is currently debt free and reviewing financing alternatives to complete construction
• The company is building 1.4 million square feet of cultivation and processing facilities across Ontario and Quebec, with the combined capacity estimated at 202,500 kilograms
• TGOD is rightsizing production in order to capture the organic segment with the optionality to add capacity as the market develops

Due to the slower pace of legal market conversion, The Green Organic Dutchman Holdings Ltd. (TSX: TGOD) (OTCQX: TGODF), a leading producer of premium-certified organic cannabis has announced a new strategic plan as the company works to enhance profitability (http://ibn.fm/Yh8cm). TGOD will optimize operating efficiency by deferring excess capacity and expenses. A new construction and operating plan to reduce cash needs has been adopted that is expected to lead towards positive operating cash flow in Q2 2020.

TGOD is reviewing financing alternatives to complete the construction at its facility at Ancaster and Phase 1 at Valleyfield (http://ibn.fm/ltNAR). The company is currently debt free with $56.7 million in cash available in Canada, including $40.2 million in restricted cash allocated to capital expenditures.

The Ancaster, Ontario site is expected to be completed by end of Q4 2019. While the greenhouse has been finished, the processing facility is mere weeks away. Once completed, the annual production in 2020 is estimated to reach 12,000 kg with the means to reach the capacity of 17,500 kg. Construction is mostly complete with all grow rooms licensed by Health Canada.

Ancaster is a purpose-built facility designed for premium organic cannabis cultivation and processing. The first harvest from the now-completed greenhouse is scheduled for Q4, around the same time that the processing facility will be completed. TGOD is working towards an EU-GMP certification that will enable exports to Europe. The focus on large-scale organic cultivation and premium pricing is expected to generate strong margins as TGOD continues to meet the highest organic standards.

Meanwhile the large-scale project in Valleyfield, Quebec, is being divided into smaller phases. This site is set to become the world’s largest organic cannabis facility at 1.31 million square feet. Once market conditions fully justify the addition, the expansion of Valleyfield will recommence, moving the initial capacity from 10,000 kg to 65,000 kg. At the completion of all phases, total planned capacity at Valleyfield will reach 185,000 kg.

“With the current Canadian legal market being smaller than initially anticipated, mainly due to a slow rollout of retail locations in key provinces, we believe that our revised plan will allow TGOD to rightsize its production to capture the organic segment, while maintaining optionality to quickly accelerate and expand as more retail locations begin to open,” TGOD CEO Brian Athaide stated in a news release.

In Canada, TGOD is building 1,40,000 square feet of cultivation and processing facilities across Ontario and Quebec. The combined planned capacity of both sites is estimated at 202,500 kg. By growing to scale and adjusting strategy to fit the changing market, TGOD can continue to deliver product the consumer has come to expect as well as profitability for investors.

The Green Organic Dutchman is building some of the most-advanced hybrid facilities in Canada capable of producing high-quality organic cannabis at some of the lowest costs today thanks to investments in facilities built to LEED certification standards and benefiting from North America’s lowest power rates in Quebec. TGOD is thinking strategically and leaving a positive impact on the communities it serves and partners with.

For more information, visit the company’s website at www.TGOD.ca

NOTE TO INVESTORS: The latest news and updates relating to TGODF are available in the company’s newsroom at  http://ibn.fm/TGODF

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Stock Jumps After FDA Announcement on Smokeless Tobacco Products

• LXRP stock jumped by 24 percent following the FDA’s announcement
• FDA recently granted the first-ever, modified-risk orders to eight smokeless tobacco products
• DehydraTECH technology enhances oral delivery of nicotine

The recent climb in the stock price of Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) looks to be the harbinger of a bright future for the innovative global developer of drug-delivery platforms. After the FDA announced it had authorized the marketing of products through the modified-risk, tobacco-product (MRTP) pathway, LXRP stock jumped 24 percent, up to $0.72 from $0.58 on the OTC Markets. The rapid rise in Lexaria stock price is a sure indication that investors are betting some of those product categories approved by the FDA could benefit from Lexaria’s drug-delivery platform. The company’s patented DehydraTECH(TM) technology has been shown to enhance the oral delivery of nicotine and a wide range of other active pharmaceutical agents.

The FDA announcement is a victory of vindication for companies such as Lexaria that are developing smokeless nicotine products and technology. While smokeless tobacco products are widely sold, in the past they cannot profess to be healthier than cigarettes to use. However, following the FDA announcement, some can. On October 22, 2019, the FDA allowed (http://ibn.fm/3hCAN) eight smokeless-tobacco products to make the claim that their use “instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.”

The FDA approval of the “modified risk” claims was made after reviewing scientific evidence submitted by the manufacturer of the products. The approvals, which are product specific and expire after five years, do not mean the products come with no health risks. Nicotine-based products are addictive and may, according to some studies, induce the onset of cardiovascular, respiratory and gastrointestinal disorders.

The patented DehydraTECH drug-delivery platform mitigates a serious limitation to nicotine ingestion. The human GI system struggles to process nicotine in the forms in which it is presently offered, one reason why there are currently no edible, nicotine, manufactured products available, although some natural foods – eggplant, green pepper, potato, tomato – do contain nicotine. However, DehydraTECH employs a delivery mechanism that improves the bioabsorption and bioavailability of many ingestible substances, as well as their taste and smell, by using lipophilic agents. Application of the technology extends beyond nicotine to non-psychoactive cannabinoids, vitamins and non-steroidal anti-inflammatory drugs (NSAIDs).

Lexaria has licensed the DehydraTECH technology to a number of companies, including one of the world’s largest tobacco corporations, in a collaboration to pursue the development of reduced-risk, oral-nicotine consumer products. Lexaria recently provided an update on that partnership. “Most of the investigation and work within this first phase of the project is either complete or significantly underway, with one remaining aspect ready to commence imminently,” the company reported (http://ibn.fm/5HjIX). “To date, results have been positive and are supportive of successfully completing this first phase. Successful completion of phase one will be the first step in developing commercially viable products using Lexaria’s technology.”

As of July 2019, Lexaria had nine corporate licensees, with whom it had signed 11 licensing agreements to develop products using its DehydraTECH absorption technology (http://ibn.fm/oyRyn). These are potentially lucrative six-figure contracts that typically yield 90 percent plus of revenues as profit. Tobacco continues to be an area of opportunity. Presently, the tobacco industry generates about 20 times more revenue than the cannabis industry.

For more information, visit the company’s website at www.LexariaBioscience.com

NOTE TO INVESTORS: The latest news and updates relating to LXRP are available in the company’s newsroom at http://ibn.fm/LXRP

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

MissionIRNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Achieves First Milestone in Cancer Quest 2020 Project

Predictive Oncology (NASDAQ: POAI), focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, this morning announced that its Helomics subsidiary has begun to sequence tumor cases from its collaboration with the UPMC Magee Women’s Hospital (http://ibn.fm/b9BBo). According to the update, the Helomics and UPMC Magee partnership focuses on analyzing the genomic and drug response profiles of women with ovarian cancer to build AI-driven predictive models’ terms of therapy response. A key benchmark in Predictive Oncology’s Cancer Quest 2020 project, the collaboration takes a retrospective look at around 400 ovarian cancer cases that Helomics profiled for drug response, for which UMPC Magee has outcome data. “These retrospective ovarian cancer cases were profiled by Helomics as early as 2010; hence, we have 10 years’ worth of drug treatment data, survival and other outcome measures we are gathering from Magee’s clinical databases,” Helomics CTO Dr. Mark Collins stated in the news release. “We are now sequencing these cases, looking at both the tumor mutations (genome) as well as tumor gene expression (transcriptome) to build a comprehensive multi-omic picture of the tumor. We are also using deep learning on histopathology images of the tumor tissue (tissue-omics) to add an additional dimension to this multi-omic profile. We believe the combination of the rich multi-omic profile of the tumor and clinical outcome data will allow us to build an AI-driven model of ovarian cancer capable of predicting the tumor drug response and patient outcome (prognosis).”

To view the full press release, visit http://ibn.fm/Okaan

About Predictive Oncology Inc.

Predictive Oncology is an AI-driven company focused on applying artificial intelligence to personalized medicine and drug discovery. The company applies smart tumor profiling and its AI platform to extensive genomic and biomarker patient data sets to predict clinical outcomes and, most importantly, improve patient outcomes for cancer patients of today and tomorrow. Predictive Oncology currently has approximately 150,000 clinically validated cases on its molecular information platform, with more than 38,000 specific to ovarian cancer. The company’s data is highly differentiated, having both drug-response data and access to historical outcome data from patients. Predictive Oncology intends to generate additional sequence data from these tumor samples to deliver on the clear unmet market need across the pharmaceutical industry for a multi-omic approach to new drug development. For more information, visit the company’s website at www.Predictive-Oncology.com.

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Predictive Oncology Inc.’s (NASDAQ: POAI) Valuable Database Offers Hope to Cancer Patients of Today and Tomorrow

• Predictive Oncology Inc. harnessing the power of artificial intelligence and its rich database of tumor data to help clinicians match cancer patients with most effective drug treatments
• Like Amazon’s customer dataset, POAI’s deep database of historical tumor information positions it for industry success
• Precision medicine is a data problem – demonstrates the huge value of data and those companies that generate it

When shopping on Amazon, it seems like the multinational technology company knows its customers intimately. Every product filtered into a search query response seems carefully curated to match each customer. This ability to leverage big data has pushed Amazon to the peak of success, and it now accounts for approximately 50 percent of all purchases made online (http://ibn.fm/0s6Qw).

Amazon’s success is a result of the company’s deep historical dataset of customer purchase profiles and its ability to leverage that with technologies such as AI. Across multiple industries from e-commerce, through finance to health care, there is now a recognition that data and the algorithms that help make sense of data are increasingly valuable and a key competitive differentiator.

From the health care field Predictive Oncology Inc. (NASDAQ: POAI) has been garnering industry attention as a hidden gem in the field of precision medicine for its innovative use of data and algorithms.

Precision Oncology is harnessing the power of artificial intelligence (think algorithms) to revolutionize treatment outcomes for cancer patients. What sets POAI apart from its competitors is the same factor that fueled Amazon’s rise: data. POAI (via its Helomics acquisition) has a huge proprietary database of tumor information, gathered from over 15+ years of clinical testing, which uniquely contains the drug responses of 150,000 individual patient tumors. Like Amazon’s database, which grows with each purchase, this unique tumor database grows daily as new tumors are tested.

While the use of data in cancer diagnostics is becoming more commonplace (think BRCA gene testing for breast cancer), for most patients the genomic data gathered from their tumor is not actionable, because researchers have a poor understanding of what mutations are important for choosing therapy. In the Amazon example, it would be like knowing people purchased dog food and cat litter but failing to predict they should buy cat food. POAI’s unique data on tumor drug response builds AI-driven predictive models that bring together the mutational and drug response profiles of the tumor to offer true actionable insights.

POAI is working with the pharmaceutical, diagnostic, and biotech industries to use its predictive models to both improve the development of new drugs (patients of tomorrow) as well as help clinicians individualize therapy (patients of today).

One disruptive aspect of POAI’s technology is that it helps the clinician to increase the chance of choosing more effective therapy, resulting in potential reduction of side-effects as well as cost savings. Traditionally oncologists prescribe what drugs they think have the best chance at beating a patient’s cancer, and the drug may or may not prove effective. Meanwhile, the patient’s undergoes chemotherapy with often debilitating side effects. If the drug proves to be a poor fit for the patient’s cancer, the chemotherapy experience will have been in vain, and the patient must continue acting as a guinea pig in experimenting with the next likely drug candidate. This is the standard cancer treatment of today. However, by utilizing POAI’s innovative tumor-profiling platform, which literally performs chemotherapy on the patient’s tumor outside the body to determine which drug is most effective, the patient can be spared many of the risks of being a “guinea-pig” as the oncologist attempts different drugs.

As Predictive leverages the data from its huge database of 150,000 of these “chemo outside the body” tests to build new predictive models, the ability to help the clinician choose the most effective drug for a patient cancer will improve. In addition, Predictive’s valuable predictive model will be a boon to the pharmaceutical industry in their race to develop new drugs to fight cancer.

For more information, visit the company’s website at www.Predictive-Oncology.com

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

MissionIRNewsBreaks – GP Solutions, Inc. (GWPD) Launches Proprietary, Cost-Effective Growth Medium

GP Solutions (OTC: GWPD), the developer of proprietary, automated micro-farms called GrowPods, on Tuesday announced the launch of Prolific, a unique, proprietary soilless growth medium and nutrient line that is free of human and sewage waste. Formulated by GP Solutions’ in-house scientists, Prolific consists of organic ingredients, requires little fertilization to sustain plant strength, and is reusable, making it cost-effective and sustainable. Prolific will be available in better garden centers, farm equipment and materials stores, and on the GP Solutions’ website. “Our objective was to develop a growth medium that will help give plants the proper nutrients they need to reach their genetic potential. Through our research and development, we created an ideal composition of natural ingredients that provide rich, contaminant-free growing conditions,” GP Solutions president George Natzic stated in the news release. “GP Solutions’ Prolific is an excellent choice for growing organic vegetables and herbs in enclosed growing environments, such as indoor farms of any size, greenhouses, potted plants, and shipping container farms. Prolific provides an all-in-one solution that is suitable for beginners, advanced gardeners, and professional farmers.”

To view the full press release, visit http://ibn.fm/zQFwH

About GP Solutions, Inc.

GP Solutions, Inc. is the developer of highly innovative automated micro-farms trade named “GrowPods.” GrowPods are a modular, stackable and mobile vertical growing environment specifically engineered to maximize yield and automation. Offering fully insulated, food-grade shipping container that has been specifically modified to provide the optimum controlled environment for growing a wide range of horticultural and agricultural products in all environments and climates. With the company’s combination of hydroponic and certified organic soil systems, clients can produce a significantly higher yield that grows faster, healthier and more consistent. For more information, visit the company’s website at www.GrowPodSolutions.com.

NOTE TO INVESTORS: The latest news and updates relating to GWPD are available in the company’s newsroom at http://ibn.fm/GWPD

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

MissionIRNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Achieves Financial Milestone via Largest Single-Hospital STREAMWAY(R) System Sale

Predictive Oncology (NASDAQ: POAI), a company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, recently announced that its Skyline Medical Division completed the sale of 10 STREAMWAY(R) Systems to a major New York hospital (http://ibn.fm/dXHwp). An article discussing the company reads, “For Predictive Oncology, this announcement represents a significant financial milestone. As POAI’s largest single-hospital transaction ever, the sale indicates the credibility and trust the STREAMWAY System is building within the industry. In addition, the sale is another positive indication that Skyline Medical, a POAI subsidiary, provides tremendous qualitative, long-term potential as it continues to focus on and develop innovative and revolutionary technology and alternatives. Through its STREAMWAY System, Skyline has achieved sales in five of the seven continents through both direct sales and distributor partners.”

To view the full article, visit http://ibn.fm/hnE61

About Predictive Oncology Inc.

Predictive Oncology is an AI-driven company focused on applying artificial intelligence to personalized medicine and drug discovery. The company applies smart tumor profiling and its AI platform to extensive genomic and biomarker patient data sets to predict clinical outcomes and, most importantly, improve patient outcomes for cancer patients of today and tomorrow. Predictive Oncology currently has approximately 150,000 clinically validated cases on its molecular information platform, with more than 38,000 specific to ovarian cancer. The company’s data is highly differentiated, having both drug-response data and access to historical outcome data from patients. Predictive Oncology intends to generate additional sequence data from these tumor samples to deliver on the clear unmet market need across the pharmaceutical industry for a multi-omic approach to new drug development. For more information, visit the company’s website at www.Predictive-Oncology.com.

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

SRAX Inc. (NASDAQ: SRAX) Continues to Empower Customers in the Digital Wave of the Future: Consumer-Managed Data

• SRAX offers a consumer-managed data marketplace through which people can own and earn from their data
• The company recently announced a co-marketing partnership with ZAPGroup
• SRAX also announced the release of an in-depth interview with The Wall Street Resource

SRAX Inc. (NASDAQ: SRAX) provides the tools to unlock the value of data across marketing channels. A digital-marketing and data-management technology company, SRAX is building the largest and most valuable opted-in data set in the world with an emphasis on privacy and data ownership. Headquartered in Los Angeles, California, SRAX offers consumers the ability to market their own data while getting paid for the release of that data.

SRAX, by way of its BIGtoken platform, has developed an innovative consumer-managed data marketplace where people can own and earn from their data. This approach is mutually beneficial, providing all players in the internet ecosystem choice, transparency, and compensation. For consumers, BIGtoken keeps their data private and they receive compensation in the form of cash or gift cards. For marketers, BIGtoken offers accurate and opted-in proprietary data to help maximize campaign targeting and performance.

Recently, SRAX announced a partnership with ZAPGroup Inc., one of the largest point-of-sale (POS) retail loyalty programs based in the Philippines (http://ibn.fm/cSYpc). This mutually beneficial, co-marketing partnership involves ZAPGroup encouraging its users to download and join BIGtoken. In return, BIGtoken will encourage its existing user base to join ZAP.

With this partnership, SRAX can sell access to valuable data, which benefits all parties involved. Additionally, when ZAP refers its users to BIGtoken, SRAX will have access to users’ opt-in data. The value to users is that those who join both platforms and agree to share their opt-in ZAP data with BIGtoken will receive extra points. These points are redeemable for select products from a ZAP retail partner.

“With this partnership, BIGtoken will provide a valuable tool to help both local and international brands and retailers understand their ROI on digital media campaigns,” said Kristoffer Nelson, CEO of SRAX and co-founder of BIGtoken. “Simultaneously, BIGtoken will expand its international reach, and SRAX will gain access to data from additional markets and advertisers.”

Moreover, SRAX recently announced a company interview by The Wall Street Resource (http://ibn.fm/7hTXX). SRAX CEO Christopher Miglino was interviewed on October 17, 2019.

The interview is available at www.TheWallStreetResource.com.

Of note regarding SRAX and its differentiator as a digital-marketing and data-management tech enterprise is that the company’s technology unlocks data to reveal brands’ core consumers and their characteristics across marketing channels. SRAX gathers everything together on one platform, delivering a digital competitive advantage for brands in the CPG (consumer packaged goods), automotive, investor-relations, luxury, and lifestyle verticals. SRAX integrates all facets of the advertising experience, including opt-in consumer participation.

SRAX executes these strategies through a diverse family of products, including SRAX Core, a custom digital-media-management platform; SRAX Social, social media marketing services; and SRAX Shopper, which delivers a cross-channel, premium digital experience at scale to high-value shopper audiences. Additional products include SRAX IR, which unlocks stock buyers’ behaviors and trends for issuers of publicly traded companies; SRAX Auto, which unlocks auto intenders’ data; and SRAX Lux, which targets and reaches luxury consumers.

SRAX continues to focus on its innovative BIGtoken platform and helping consumers as they become more aware of the value of their data. With more than 16 million users globally, the company is proving that consumers are interested in their data and want to receive compensation by marketers while their privacy concerns are respected. Furthermore, SRAX offers investors the potential for significant ROI in a digital vertical that is the wave of the future, consumer-managed data.

For more information, visit the company’s website at www.SRAX.com

NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://ibn.fm/SRAX

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

SRAX Inc. (NASDAQ: SRAX) Presents at Premier Microcap Investor Conference

• SRAX’s CEO presented at the Microcap Rodeo Investor Conference held October 15 in Austin, Texas
• The company’s BIGtoken offers an innovative way for consumers to own and earn from their data
• The company aims to become a household name in the data management sector

SRAX Inc. (NASDAQ: SRAX) CEO Christopher Miglino presented at the Microcap Rodeo Investor Conference held at the Hilton Austin Downtown in Austin, Texas on October 15. The theme of the conference, ‘Lassoing the Best Ideas’, aptly encompasses SRAX. SRAX’s innovative strategy to solve the problem of consumer consent to release data is aiding it in its quest to build the largest opted-in data set in the world.

SRAX’s innovative BIGtoken platform requests permission from its users for data sharing when those users sign up on the platform (http://ibn.fm/LbKG2). SRAX is ahead of the competition in using this approach. In California, a new privacy law compliance bill goes into effect January 1, 2020, requiring users to provide this permission before their information can be shared. The law is designed to protect the privacy of consumers, a responsibility SRAX has taken seriously since the inception of its BIGtoken app.

A recent CNBC report noted that the legislation could mean that some firms may have to pay in aggregate up to $55 million in initial compliance costs, according to an assessment prepared by an independent research firm for the state attorney general’s office in California (http://ibn.fm/LrIWb). Thanks to BIGtoken, SRAX is already in compliance with the legislation.

SRAX is a digital marketing and consumer data management technology company that has developed a first-of-its-kind data management platform. The company’s proprietary BIGtoken platform offers a secure and transparent environment for consumers to own and earn from their data (http://ibn.fm/jXGBN). The SRAX product offers consumers key control over their own privacy and also unlocks the value of their data. The Microcap Rodeo Investor Conference (http://ibn.fm/pYQAc) offered investors the firsthand opportunity to hear details about BIGtoken and the company’s strategy from Miglino himself.

The annual Austin conference offers investors the chance to harness top stocks for their portfolios. Executive management teams from more than 50 microcap companies across a wide variety of industries attended this year’s event, which featured four tracks of diverse company presentations along with an interactive, in-depth format of face-to-face meetings.

SRAX’s technology dually benefits both individual consumers and the companies seeking to utilize their data. For the latter, SRAX sells access to data in the form of anonymized segments. BIGtoken unlocks data to reveal the core customers of brands and the characteristics of those consumers across marketing channels. Individual consumers utilize the BIGtoken platform to control access to their information at any time. By creating a mutually beneficial way to help consumers market themselves while also protecting their privacy, the company is building the largest and most valuable opted-in data set worldwide. Through the added exposure gained from Miglino’s appearance at the Microcap Rodeo Investor Conference, the company is poised to become a household name in the data management sector.

For more information, visit the company’s website at www.SRAX.com

NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at  http://ibn.fm/SRAX

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html